Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chaouki Khoury

Neurology with Special Qualifications in Child Neurology Atlanta, GA Medical Doctor

NPI 1831223049 CMS profile 173575

5887 Glenridge Dr Ste 140, Atlanta, GA 30328

Open in the dashboard

General payments

$978,323

2,236 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$28,339 paid to institutions, not to them · program year 2025

Through program year 2025, Chaouki Khoury of Atlanta, GA is reported in the CMS Open Payments database as having received $978,323 across 2,236 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $28,339 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $249,711 413
2024 General $180,929 357
2023 General $196,829 417
2022 General $204,090 468
2021 General $116,488 325
2020 General $28,394 179
2019 General $1,883 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chaouki Khoury
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Chaouki Khoury were reported at $249,711. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Chaouki Khoury Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $1,883 $262 $68–$1,313 $163
2020 $28,394 $188 $46–$1,222 $114
2021 $116,488 $183 $45–$1,356 $132
2022 $204,090 $229 $72–$1,177 $149
2023 $196,829 $269 $93–$1,195 $160
2024 $180,929 $300 $98–$1,428 $164
2025 $249,711 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $537,710 709 payments
  2. Lundbeck LLC $244,106 409 payments
  3. Biohaven Pharmaceuticals, Inc. $60,547 93 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $31,779 57 payments
  5. Impel Pharmaceuticals Inc. $27,463 51 payments
  6. Axsome Therapeutics, Inc. $23,765 42 payments
  7. Allergan Inc. $19,087 77 payments
  8. Pfizer Inc. $6,169 63 payments
  9. Impel Pharmaceuticals LLC $4,871 12 payments
  10. Upsher-Smith Laboratories LLC $3,426 58 payments
  11. Other $19,399 665 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $559,800 221 payments
  2. Honoraria $164,344 52 payments
  3. Travel and Lodging $108,448 443 payments
  4. Consulting Fee $102,587 91 payments
  5. Food and Beverage $43,137 1,427 payments
  6. Education $7 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $420,226 475 payments
  2. QULIPTA $324,455 395 payments
  3. VYEPTI Neurology $192,818 287 payments
  4. NURTEC ODT Primary Care $92,326 150 payments
  5. VYEPTI Neurology $52,440 121 payments
  6. Trudhesa Migraine $17,609 22 payments
  7. Symbravo $16,065 29 payments
  8. UBRELVY Neuroscience $14,917 44 payments
  9. Trudhesa Neurology $9,854 29 payments
  10. NURTEC ODT Pain $6,112 59 payments
  11. Other $32,055 949 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

163

Median for Psychiatry & Neurology: 100

Drug cost

$39,123

Median for Psychiatry & Neurology: $2,986

Branded share of claims

16%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 15 $24,348
Qulipta Atogepant Brand 11 $11,301
Vilazodone Hcl Generic 13 $1,311
Duloxetine Hcl Generic 26 $604
Divalproex Sodium Generic 13 $536
Doxepin Hcl Generic 13 $510
Ramelteon Generic 11 $275
Cyclobenzaprine Hcl Generic 13 $100
Clonazepam Generic 13 $49
Sumatriptan Succinate Generic 12 $49

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
$71,388 — —
UBRELVY
$54,293 15 —
QULIPTA
$51,353 11 —
Qelbree
$459 — —
NURTEC ODT
$382 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

2,236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record